[go: up one dir, main page]

NZ504106A - Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them - Google Patents

Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
NZ504106A
NZ504106A NZ504106A NZ50410698A NZ504106A NZ 504106 A NZ504106 A NZ 504106A NZ 504106 A NZ504106 A NZ 504106A NZ 50410698 A NZ50410698 A NZ 50410698A NZ 504106 A NZ504106 A NZ 504106A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutically acceptable
compositions containing
compounds
pipyridine
thiazine
Prior art date
Application number
NZ504106A
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Ashok Channaveerappa Bajji
Shivaramayya Kalchar
Rajagopalan Ramanujam
Ranjan Chakrabarti
Original Assignee
Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/085,292 external-priority patent/US6265401B1/en
Application filed by Dr filed Critical Dr
Publication of NZ504106A publication Critical patent/NZ504106A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel beta -aryl- alpha -oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
NZ504106A 1998-05-27 1998-10-26 Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them NZ504106A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/085,292 US6265401B1 (en) 1997-10-27 1998-05-27 Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
PCT/US1998/022570 WO1999020614A1 (en) 1998-05-27 1998-10-26 Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
NZ504106A true NZ504106A (en) 2003-02-28

Family

ID=22190649

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504106A NZ504106A (en) 1998-05-27 1998-10-26 Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them

Country Status (6)

Country Link
EP (1) EP1082313A1 (en)
JP (1) JP2002507543A (en)
CN (1) CN100357281C (en)
NZ (1) NZ504106A (en)
PL (1) PL341795A1 (en)
WO (1) WO1999020614A1 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2355645A1 (en) * 1998-12-17 2000-06-22 Mindset Biopharmaceuticals (Usa), Inc. Increasing brain glucose utilization
US6528507B1 (en) 1999-04-16 2003-03-04 Dr. Reddy's Laboratories Limited Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
WO2000063189A1 (en) * 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
TR200103851T2 (en) * 1999-04-16 2002-04-22 Dr. Reddy' S Research Foundation New polymorphic forms of an antidiabetic agent, the process for their preparation, and pharmaceutical compositions thereof
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
EP1171431A1 (en) * 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
PL351312A1 (en) * 1999-04-20 2003-04-07 Novo Nordisk As New compounds, their preparation and use
WO2000063209A1 (en) * 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
US6369055B1 (en) 1999-04-20 2002-04-09 Novo Nordisk A/S Compounds, their preparation and use
CZ20013832A3 (en) * 1999-04-28 2002-04-17 Dr. Reddy's Research Foundation Substituted bicyclic heterocyclic compounds, process of their preparation and their use as agents reducing obesity and hypocholesterolaemic agents
CZ304346B6 (en) * 2000-01-19 2014-03-19 Cadila Healthcare Ltd. Substituted pyrrole derivative exhibiting hypolipidemic and hypocholesteremic activity , process for its preparation and pharmaceutical composition containing thereof
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
IL150260A0 (en) * 2000-01-28 2002-12-01 Novo Nordisk As Propionic acid derivatives and their use in the treatment of diabetes and obesity
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
AU2001263083A1 (en) * 2000-05-12 2001-11-26 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4h-benzo(1,4)oxazin-3-ones
US6599899B2 (en) 2000-05-12 2003-07-29 Ortho-Mcneil Pharmaceutical, Inc. Benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
WO2001087861A2 (en) * 2000-05-12 2001-11-22 Ortho-Mcneil Pharmaceutical, Inc. Methods of treatment using benzoxazinones as peroxisome proliferator activated receptor gamma modulators
US6908908B2 (en) * 2000-05-12 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4H-benzo [1,4] oxazin-3-ones
AU2001284335A1 (en) * 2000-09-04 2002-03-22 Dr. Reddy's Research Foundation Process for the preparation of 2-(3,4-dihydro-1,4-benzothiazin-4-yl)ethylmethane sulphonate
AU2002212672A1 (en) * 2000-10-12 2002-04-22 Dr. Reddy's Research Foundation Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
SI1355644T1 (en) 2001-01-26 2006-10-31 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
US20020198202A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an antilipemic agent
WO2003006022A1 (en) * 2001-07-09 2003-01-23 Dr. Reddy's Laboratories Ltd. Tetrahydroquinoline derivatives and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DK1429756T3 (en) 2001-09-21 2007-03-19 Schering Corp Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
CA2463685A1 (en) 2001-10-16 2003-04-24 Dr. Reddy's Laboratories Ltd. Novel .beta.-phenyl-.alpha.-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
WO2003099800A1 (en) * 2002-05-23 2003-12-04 Dr. Reddy's Laboratories Limited An improved process for the preparation of bicyclic antidiabetic agents
US20040092499A1 (en) 2002-11-06 2004-05-13 Schering Corporation Methods and therapeutic combinations for the treatment of autoimmune disorders
ATE418551T1 (en) 2003-03-07 2009-01-15 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (en) 2003-03-07 2006-04-05 先灵公司 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR101733414B1 (en) 2011-01-31 2017-05-10 카딜라 핼쓰캐어 리미티드 Treatment for lipodystrophy
BR112013021236B1 (en) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp benzimidazole derivative compound, and, composition
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2015010935A (en) 2013-02-22 2015-10-29 Merck Sharp & Dohme Antidiabetic bicyclic compounds.
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014174524A1 (en) 2013-04-22 2014-10-30 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
MX2015016403A (en) 2013-05-30 2016-04-11 Cadila Healthcare Ltd A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities.
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
TW201636015A (en) 2013-07-05 2016-10-16 卡地拉保健有限公司 Synergistic compositions
IN2013MU02470A (en) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
MX382765B (en) 2016-12-09 2025-03-13 Zydus Lifesciences Ltd TREATMENT FOR PRIMARY BILIARY CHOLANGITIS.
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110092774B (en) * 2018-01-29 2022-04-08 中国科学院上海药物研究所 Aromatic propionic acid derivative, preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173350B1 (en) * 1985-02-26 2000-08-07 Sankyo Co Thiazolidine derivatives, their preparation and pharmaceutical composition containing them
US5496815A (en) * 1990-02-08 1996-03-05 Tanabe Seiyaku Co., Ltd. Thiazine (or oxazine) derivatives and preparation thereof
CA2035147A1 (en) * 1990-02-08 1991-08-09 Kousuke Yasuda Thiazine (or oxazine) derivatives and preparation thereof
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
JPH05194236A (en) * 1991-07-25 1993-08-03 Tanabe Seiyaku Co Ltd Central calcium channel blocker
WO1996004261A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
JPH0912575A (en) * 1995-06-28 1997-01-14 Sankyo Co Ltd Benzoxazine and benzothiazine derivative

Also Published As

Publication number Publication date
EP1082313A1 (en) 2001-03-14
WO1999020614A1 (en) 1999-04-29
JP2002507543A (en) 2002-03-12
CN1281443A (en) 2001-01-24
PL341795A1 (en) 2001-05-07
CN100357281C (en) 2007-12-26

Similar Documents

Publication Publication Date Title
NZ504106A (en) Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
MY121760A (en) Benzothiazin and benzoxazin derivatives;their preparation and uses
WO1999008501A3 (en) New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
YU60701A (en) Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical composition containing them
IL127296A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
YU75101A (en) Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
MY140057A (en) Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine
CA2258949A1 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
MXPA04005257A (en) New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them.
MXPA02012033A (en) 2-aminocarbonyl-9h-purine derivatives.
AU6966498A (en) Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypol ipidaemic and antihypertensive properties
YU52403A (en) Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
MXPA03000161A (en) Novel compounds having antiinflammatory activity: process for their preparation and pharmaceutical compositions containing them.
BG106932A (en) Novel compounds having hypolipedemic and hypocholesteremic activities, processes for their preparation and pharmaceutical compositions containing them
NZ216048A (en) Quinolylglycinamide derivatives, and pharmaceutical compositions containing such
NZ210100A (en) 5h,11h-pyrrolo(2,1-c)(1,4)benzoxazepine derivatives and pharmaceutical compositons
UA72883C2 (en) Bicyclic compounds, a method for preparing thereof and pharmaceutical compositions containing them
YU76500A (en) Chemical synthesis of morpholine derivatives
AU7109798A (en) Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypol ipidemia and antihypertensive properties
CA2307068A1 (en) Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
MXPA04002784A (en) Pharmaceutically acceptable salts of 20(s)-camptothecins.
MY131832A (en) New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
MXPA04003628A (en) Benzoxazine and benzothiazine derivatives and parmaceutical compositions containing them.
AU6663596A (en) One pot synthesis of 2-oxazolidinone derivatives
ES2103237A1 (en) New compound derived from chromene

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: DR. REDDY S LABORATORIES LIMITED, IN

Free format text: OLD OWNER(S): REDDY-CHEMINOR, INC.; DR. REDDY S RESEARCH FOUNDATION

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)